Results of therapy for Hodgkin’s disease in childhood

Sackmann‐Muriel, Federico; Maschio, Mabel; Santarelli, María Teresa; Pavlovsky, Santiago

doi:10.1007/978-1-4613-1739-5_21

Cited by 8 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Failure to respond to treatment (5.5%), toxicity (5.5%), CNS and local relapse (5.5%), and infections (4%) were the main causes of death in the 73 patients, as was found in other reported studies [10,11,21]. Toxic deaths were reduced from 9% in G-A to 0% in G-B after modifications to supportive care and changing ADRIA for epirubicin.…”

Section: Resultssupporting

confidence: 51%

“…In Europe, 69% of 42 patients with ANHL survived after treatment with CPM-VCR-P-ADR-MTX-araC and thioguanine [ 111. In Latin America, the results for two groups of patients with ANHL, treated with surgery, chemotherapy (CPM-VCR-P-6MP-MTX), and radiotherapy showed 49 and 58% survivors [7,10] while 84% survived after only chemotherapy [9].…”

Section: Resultsmentioning

confidence: 99%

“…In Latin America, ANHL is found in 55 to 75% of cases of NHL [7,8], usually in children under 6 years old. The response to less aggressive chemotherapy and the survival rates of the stage 111 cases are better than in countries in the north hemisphere [7,9,10]. Conversely, in the United States and Europe, abdominal localization is found only in 35 to 50% and usually in children aged 8 years or older [4,11] and the response to moderately intensive chemotherapy schedules is poor [6,12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Stage III abdominal non‐Hodgkin's lymphoma in costa rican children: Comparison of two consecutive trials of treatment

Lobo-Sanahuja¹,

García²,

Barrantes³

et al. 1994

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Seventy-three patients with Stage III abdominal non-Hodgkin's lymphoma were prospectively treated following two sequential protocols (P): L278 P (group A, 33 patients) (1978-1983) and L384 P (group B, 40 patients), (1984-1991). No patient received radiotherapy. The L278 P included 7 drugs: cyclophosphamide, vincristine (VCR), adriamycin (ADR), prednisone, methotrexate (MTX), dexamethasone, and 6-mercaptopurine, given for remission induction, maintenance, and CNS prophylaxis. In the L384 P we introduced a consolidation phase consisting of intravenous MTX and citrovorum factor rescue, and IV cytosine arabinoside. VCR was also added to the monthly doses and the maintenance phase was reduced from 18 to 15 months. From January 1988 we changed ADR for epirubicin in the same doses. Prophylactic treatment of the CNS, in the L384 P, was intensified by increasing the number of doses of MTX IT in the remission, induction, and consolidation phases, and with the use of ara-C IT. Laparotomy in 50 patients allowed partial resection in 16, and second-look laparotomy was performed in 27 patients. Viable tumor was found in four patients. Three patients (G-A) died from metabolic complications and another 4 (2 G-A and 2 G-B) failed to attain CR and died. A total of 28 (85%) of 33 children of G-A and 38 (95%) of 40 children in G-B achieved CR. Five children died in remission (2 G-A, 3 G-B). Three patients (G-A) relapsed in the CNS and one (G-B) relapsed in the abdomen and died. Disease-free survival at 120 months was 70% in G-A and 84% in G-B.

show abstract

Section: Resultssupporting

confidence: 51%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Stage III abdominal non‐Hodgkin's lymphoma in costa rican children: Comparison of two consecutive trials of treatment

Lobo-Sanahuja¹,

García²,

Barrantes³

et al. 1994

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

show abstract

Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy

Berg

Stuve

Behrendt

1997

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Sackmann‐Muriel

Zubizarreta

Gallo

et al. 1997

Med. Pediatr. Oncol.

Self Cite

View full text Add to dashboard Cite

Purpose To compare prospective treatment strategies in childhood Hodgkin disease to the following subsets of patients: a) Favorable prognostic group: these patients were randomized to receive 6 vs. 3 CVPP chemotherapy cycles without radiotherapy (CVPP: cyclophosphamide, vinblastine, procarbazine, and prednisone. The scheme was repeated every 28 days). b) Intermediate prognostic group: these patients were randomized to receive 6 cycles of CVPP or AOPE (AOPE: Adriamycin, vincristine, prednisone, and etoposide). Between the third and fourth cycles, all patients in this group received radiotherapy (RT)(30–40 Gy to initially involved areas). c) Unfavorable prognostic group: those patients received a single arm regimen of 6 cycles of CCOPP/CAPTe (3 of each combination) every 28 days. All these patients received radiotherapy (30–40 Gy to initially involved areas). Results From October 1987 to December 1994, a total of 114 children and adolescents were evaluated. Mean age was 9 (range 2–17) years. There were 72 boys and 42 girls. With a median follow‐up of 5 (range 1.5–8.7) years, at 80 months event‐free survival (EFS) and overall survival (OS) for the whole cohort are 0.809 (SE: 0.04) and 0.873 (SE: 0.04), respectively (SE: Standard Error). Favorable prognostic group (n = 26) EFS is 0.831 (0.09) (Arm CVPP × 3: 0.857 (0.13) and Arm CVPP × 6: 0.875 (0.08); p = non significant). Intermediate prognostic group (n = 64) EFS is 0.806 (0.05) (Arm CVPP × 6 + RT: 0.872 (0.05) and Arm AOPE × 6 + RT: 0.667 (0.10); p = 0.04). Unfavorable group (n = 24) EFS is 0.829 (0.07). Conclusions Results of treatment for the whole group are satisfactory. However, 3 cycles of CVPP without radiotherapy obtain equal EFS than 6 cycles without radiotherapy in the favorable prognostic group. In the intermediate prognostic group, 6 cycles of CVPP plus radiotherapy obtain a superior EFS than 6 cycles of AOPE plus radiotherapy. With the success of treatment for Hodgkin disease in children, future research needs to be focused in reducing toxicity without altering the excellent actual outcome. Med. Pediatr. Oncol. 29:544–552, 1997. © 1997 Wiley‐Liss, Inc.

show abstract

Results of therapy for Hodgkin’s disease in childhood

Cited by 8 publications

References 2 publications

Stage III abdominal non‐Hodgkin's lymphoma in costa rican children: Comparison of two consecutive trials of treatment

Stage III abdominal non‐Hodgkin's lymphoma in costa rican children: Comparison of two consecutive trials of treatment

Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy

Hodgkin disease in children: Results of a prospective randomized trial in a single institution in Argentina

Contact Info

Product

Resources

About